TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from Lepu Biopharma Co. Ltd. Class H ( (HK:2157) ) is now available.
Lepu Biopharma Co., Ltd. announced that its Phase IIb study results for MRG003, an innovative ADC targeting EGFR for recurrent or metastatic nasopharyngeal cancer, have been selected for oral presentation at the 2025 ASCO Annual Meeting. This recognition highlights the potential impact of MRG003 in cancer treatment, although the company cautions that successful development and marketing are not guaranteed, advising shareholders and investors to exercise caution.
More about Lepu Biopharma Co. Ltd. Class H
Lepu Biopharma Co., Ltd. is a pharmaceutical company based in China, focusing on the development of innovative antibody drug conjugates (ADCs) targeting various cancers. The company is involved in creating treatments for conditions such as nasopharyngeal cancer, leveraging its expertise in targeting epidermal growth factor receptors (EGFR) which are prevalent in several malignant tumors.
YTD Price Performance: 19.47%
Average Trading Volume: 8,579,545
Technical Sentiment Signal: Hold
Current Market Cap: HK$5.35B
For a thorough assessment of 2157 stock, go to TipRanks’ Stock Analysis page.